BlackRock Amends 10x Genomics Stake, Signals Portfolio Adjustment
Ticker: TXG · Form: SC 13G/A · Filed: Jan 31, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | SC 13G/A |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, portfolio-change
TL;DR
**BlackRock just updated its 10x Genomics stake, watch for potential market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 31, 2024, indicating a change in their ownership of 10x Genomics, Inc. (NASDAQ: TXG) common stock as of December 31, 2023. This update, Amendment No. 5, signals that BlackRock, a major institutional investor, has adjusted its stake in the laboratory analytical instruments company. For investors, this matters because large institutional movements can influence stock price and reflect a significant investor's updated view on the company's prospects.
Why It Matters
This filing shows that a major institutional investor, BlackRock, has changed its position in 10x Genomics, which can be a signal to the market about the stock's attractiveness.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and doesn't inherently signal high risk, but rather a portfolio adjustment.
Analyst Insight
Smart investors should monitor BlackRock's future filings and 10x Genomics' upcoming earnings reports to understand the rationale behind this portfolio adjustment and its potential impact on the stock.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- 10x Genomics, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 31, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 5 (number) — the specific amendment number of the filing
Forward-Looking Statements
- BlackRock's adjusted stake in 10x Genomics will lead to increased market scrutiny of TXG's performance. (10x Genomics, Inc.) — medium confidence, target: Q1 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 5, as stated in the filing.
Who is the reporting person in this filing?
The reporting person, or the entity that filed this statement, is BlackRock Inc., as indicated in the 'FILED BY' section of the filing.
What is the subject company whose securities are being reported?
The subject company is 10x Genomics, Inc., as identified in the 'SUBJECT COMPANY' section and on the Schedule 13G form itself.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of 10x Genomics, Inc. is 88025U109, as stated on the cover page of the Schedule 13G.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified on the Schedule 13G cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 31, 2024 regarding 10x Genomics, Inc. (TXG).